The immunologic efficacy of the different external immunostimulant conditions used in combination with the autologous tumor lysate-loaded DC vaccine will be assessed by DTH development against KLH and tumor homogenate and also by IFN-γ-ELISPOT analysis of circulating effectors specific for tumor antigens known to be expressed in melanoma, as described in the “Immunologic endpoint assessment” section. This evidence concerns the gene IFNG and neoplasm.